Global HCQ/CQ studies

December 18, 2020 @CovidAnalysis

	Early treatment65%100% of studies report positive effects. 65% improvement from meta analysis, p<0.0001.206 HCQ studies 140 peer reviewedLate (27%)27%Treatment27%78% of studies report positive effects.high efficacy
12/16	Early, Covid Analysis meta-analysis HCQ is effective for COVID-19 when used ea • HCQ is effective for COVID-19. The probability that an ineffective treatment generated results as
12/16	LateSignes-Costadeath, ↓47.0%, pPrevalence and 30-day mortality in hospitaliz47% lower mortality with HCQ/CQ. Retrospective 1,271 patients with lung disease in Canada, Chin
12/14	LateOrioli et al., Diadeath, ↓12.7%, pClinical characteristics and short-term prognSmall retrospective study of 73 diabetic patients in Belgium, 55 HCQ patients, showing HCQ RR 0
12/14	LateNaseem et al.,death, ↓33.3%, pPredicting mortality in SARS-COV-2 (COVIDRetrospective 1,214 hospitalized patients in Pakistan, 77 HCQ patients, showing 33% lower mortal
12/14	LateTan et al., Viruhosp. time, 135.2A retrospective comparison of drugs againstRetrospective 333 patients in China, with only 8 HCQ patients, showing shorter duration of hospita
12/11	LateBielza et al., Jodeath, ↓21.5%, pClinical characteristics, frailty and mortalityRetrospective 630 elderly patients in Spain showing lower mortality with HCQ treatment, unadjust
12/11	EarlySogut et al., Thsafety analysisSafety and efficacy of hydroxychloroquine inSafety study of 152 outpatients concluding that HCQ is safe for COVID-19, was well tolerated, and
12/11	PrEP Jung et al., Cli death, ↓59.3%, p Effect of hydroxychloroquine pre-exposure o

	Retrospective cohort study of RA and SLE patients not showing a significant difference in PCR+ c
12/10	LateAlqassieh et alhosp. time, 18.2Clinical characteristics and predictors of theProspective observational study of 131 COVID-19 patients in Jordan, showing 18% shorter hospita
12/10	NewsItalian CouncilnewsConsiglio di Stato, sì all'uso dell'idrossicloracConsiglio di Stato ruling in Italy re-establishes the right of Italian MDs to prescribe HCQ, which was
12/9	EarlyAgusti et al., Eprogression, ↓68Efficacy and safety of hydroxychloroquine inSmall trial of low dose HCQ for healthcare workers with mild SARS-CoV-2 showing 68% lower prog
12/9	Late Guglielmetti et death, ↓35.0%, p Severe COVID-19 pneumonia in Piacenza, Ita Retrospective 218 hospitalized patients in Italy showing non-statistically significant 35% lower mo
12/7	PEP Barnabas et al hosp., ↑3.7% , p=1 Hydroxychloroquine for Post-exposure Prop Early terminated PEP RCT comparing HCQ and vitamin C with 781 low-risk patients (83% househo
12/4	LateOzturk et al., Ndeath, ↓43.9%, pMortality analysis of COVID-19 infection in cRetrospective 1210 hospitalized patients in Turkey focused on chronic kidney disease, haemodialy
12/4	LateModrák et al.,death, ↓59.0%, pDetailed disease progression of 213 patientsRetrospective 213 hospitalized patients in Czech Republic showing lower mortality with HCQ. Subj
12/4	LatePeng et al., Neprogression, ↓10Early versus late acute kidney injury amongRetrospective 4020 hospitalized patients in China showing non-statistically significant lower risk o
12/2	PEP Wiseman et al cases, ↓42.0%, p Effective post-exposure prophylaxis of Covid 6th independent analysis showing efficacy from the Boulware PEP trial. This prospective analysis
12/1	Late Capsoni et al., ventilation, 140.0 CPAP Treatment In COVID-19 Patients: A Ret Small 52 patient retrospective study of patients with acute respiratory failure showing lower rates
11/30	LateAbdulrahmandeath, ↓16.7%, pThe efficacy and safety of hydroxychloroquinRetrospective medical record analysis of acute care patients in Bahrain not showing a significant
11/29	LateAbd-Elsalam et al., Biological Trace ElDo Zinc Supplements Enhance the Clinical E191 patient RCT in Egypt comparing the addition of zinc to HCQ, not showing a significant differen
11/28	Late Lambermont e death, ↓32.3%, p Predictors of Mortality and Effect of Drug Th Retrospective 247 mechanically ventilated patients showing lower mortality with HCQ, but not stat
11/28	N/A <i>Ruiz</i> et al., Inte dosing study Hydroxychloroquine lung pharmacokinetics i

	HCQ lung pharmacokinetic study confirming that lung concentrations can be much higher than pl
11/28	LateRedriguez-Gondeath, 122.8%, pCOVID-19 in hospitalized patients in Spain: aRetrospective 1255 patients in Spain showing lower mortality with HCQ. Subject to confounding b
11/27	Latevan Halem et adeath, J31.6%, pRisk factors for mortality in hospitalized patiRetrospective 319 hospitalized patients in Belgium showing lower mortality with HCQ, although no
11/24	LateAbbas et al., Int. J. Clin. Pract., doi:10Assessment of COVID-19 Treatment containProspective study of 161 hospitalized patients in Iraq showing HCQ+AZ appears to help recovery
11/23	LateQin et al., Throdeath, J34.3%, pLow molecular weight heparin and 28-day mLow molecular weight heparin study also showing results for HCQ treatment, unadjusted HCQ mo
11/21	PrEPRevollo et al., Jcases, 123.0%, pHydroxychloroquine pre-exposure prophylaxiRetrospective PrEP analysis with 69 healthcare workers on PrEP HCQ, and 418 control. Authors re
11/20	Early Omrani et al., E hosp., 12.5%, p= Randomized double-blinded placebo-controll Low risk patient RCT for HCQ+AZ and HCQ vs. control, not showing any significant differences. Au
11/19	LateFalcone et al.,death, 165.0%, pRole of low-molecular weight heparin in hosProspective observational study of 315 hospitalized patients in Italy showing 65% lower mortality
11/18	LateBudhiraja et aldeath, ↓65.4%, p<
11/17	LateBoari et al, Biodeath, ↓54.5%, p<
11/13	LateSheshah et al.,death, ↓80.0%, p<
11/12	Early Simova et al., hosp., ↓93.8%, p= Hydroxychloroquine for prophylaxis and trea 100% reduction in hospitalization and cases with early treatment using HCQ+AZ+zinc. Brief report
11/12	PEPSimova et al.,cases, 192.7%, pHydroxychloroquine for prophylaxis and trea100% reduction in cases with HCQ+zinc post-exposure prophylaxis. Brief report for healthcare wor
11/12	N/ATchounga et almeta-analysisComposition analysis of falsified chloroquinAnalysis of fake CQ tablets finding: - no CQ in six samples, substituted with metronidazole (at sub
11/11	

	Late 67% lowe	Águila-Gordo e er mortality with HC	death, ↓67.0% , p Q. Retrospective 416 el	Mortality and associated prognostic fa derly patients in Spain showing adjusted	
11/9	Late Small 89		rnational Journal of ring favipiravir and inha	Randomized Controlled Open Label Tria	
11/9	Late Early terr	<i>Self</i> et al., JAM ninated very late sta	death, ↓ 7.0% , p= age (65% on supplemer	Effect of Hydroxychloroquine on Clinicantal oxygen) RCT with 242 HCQ and 237 o	
11/9	Late Small ea		's of the American T ate stage (86% on oxyg	Hydroxychloroquine vs. Azithromycin fo Jen, 44% enrolled in the ICU) RCT compar	
11/9	Late Retrospe	Núñez-Gil et al ective database stud	death, ↓ 7.9% , p= y of 1,021 patients in E	Mortality risk assessment in Spain and cuador, Germany, Italy, and Spain, showir	-
11/6	PrEP 90% redu	<i>Mathai</i> et al., J Iction in cases with	cases, ↓89.5% , p HCQ pre-exposure prop	Hydroxychloroquine as pre-exposure probylaxis. Retrospective 604 healthcare wo	
11/6	PrEP Survey o		al of Vaccines & Vac finding a significant eff	No Role of HCQ in COVID-19 Prophylax fect of HCQ prophylaxis, <i>p</i> = 0.54. We do r	
11/6	PEP 41% redu	Dhibar et al., In action in cases with	cases, ↓41.0% , p HCQ PEP. Prospective o	Post Exposure Prophylaxis with Hydrox open label trial with 132 HCQ patients and	-
11/5	Late Small ret	Maldonado et rospective 12 dialys	death, ↓90.9% , p is patients, 1/11 death	COVID-19 incidence and outcomes in a swith HCQ and 1/1 without HCQ.	ı hom
11/5	Late Retrospe	Rodriguez-Nav active 313 patients, r	death, ↑6.3% , p= nostly critical stage and	Clinical characteristics and risk factors d mostly requiring respiratory support, sh	
11/4	Early Compari	<i>Cadegiani</i> et al son of HCQ, nitazoxa	death, ↓ 81.2% , p anide, and ivermectin s	Early COVID-19 Therapy with Azithromy howing similar effectiveness for overall c	, ,
11/3	PrEP Retrospe		cases, ↓27.9% , p udy for HCQ, ivermectir	Role of ivermectin in the prevention of the and vitamin C with 372 healthcare work	
11/2	Late Retrospe	<i>López</i> et al., A ective 72 pediatric pa	progression, ↓ 64. atients showing HCQ as	Telemedicine follow-ups for COVID-19: ssociated with a shorter duration of fever	
10/31	Early 64% lowe	Fonseca et al., er hospitalization wit	hosp., ↓64.0% , p= th HCQ. Retrospective	Risk of Hospitalization for Covid-19 Ou 717 patients in Brazil with early treatment	

10/30	Late Tehrani et al., I death, \downarrow 13.4%, p Risk factors for mortality in adult COVID-19 Retrospective 255 hospitalized patients, 65 treated with HCQ, showing unadjusted RR 0.87, p=0.6
10/27	PrEP Arleo et al., me death, 150.0%, p Clinical Course and Outcomes of coronaviru Retrospective hospitalized rheumatic disease patients showing 50% lower mortality for patients o
10/27	Late Choi et al., Inte viral- time, ↑22.0 Comparison of antiviral effect for mild-to-mo Health insurance database analysis failing to adjust for disease severity and not finding a significa
10/26	Late Frontera et al., death, ↓37.0%, p Treatment with Zinc is Associated with Redu Retrospective 3,473 hospitalized patients showing lower mortality with HCQ+zinc.
10/26	EarlyDerwand et al.,death, ↓79.4%, pCOVID-19 Outpatients – Early Risk-Stratified79% lower mortality and 82% lower hospitalization with early HCQ+AZ+Z. No cardiac side effects
10/24	PrEP <i>Goenka et al.,</i> IgG+, J87.2% , p= Seroprevalence of COVID-19 Amongst Healt Study of SARS-CoV-2-IgG antibodies in 1122 health care workers in India finding 87% lower positiv
10/23	LateColl et al., Amedeath, ↓45.6%, p<
10/21	LateLano et al., Clideath, \downarrow 33.1%, pRisk factors for severity of COVID-19 in chro33% lower mortality with HCQ+AZ, p =0.28. Retrospective 122 French dialysis patients. 69% lower
10/21	LateDubee et al., mdeath, 146.0%, pA placebo-controlled double blind trial of hydSmall early terminated late stage (60% on oxygen) RCT in France showing 46% lower mortality. m
10/21	Late <i>Ñamendys-Silv</i> death, ↓32.3% , p Outcomes of patients with COVID-19 in the I Retrospective 164 ICU patients in Mexico showing 32% lower mortality with HCQ+AZ and 37% low
10/20	Early, IHU Marseille (meta-analysis Meta-analysis on chloroquine derivatives an Updated meta analysis of 41 studies showing CQ/HCQ OR 0.57, <i>p</i> <0.0001 from clinical studies. Fo
10/20	LateSolh et al., medeath, ↑18.0%, pClinical course and outcome of COVID-19 acRetrospective database analysis of 7,816 Veterans Affairs hospitalized patients analyzing progres
10/17	EarlyMohana et al.,safety analysisHydroxychloroquine Safety Outcome withinSafety study of 2,733 patients in Saudi Arabia showing HCQ in mild to moderate cases in an outpa
10/15	Late <i>Guisado-Vasc</i> death, ↓20.3%, p Clinical characteristics and outcomes amon Retrospective 607 patients reporting results for early outpatient HCQ use with mortality odds ratio

10/15	Late SOLIDARITY <i>Tr</i> death , ↑19.0% , p Repurposed antiviral drugs for COVID-19; int WHO SOLIDARITY open-label trial with 954 very late stage (64% on oxygen/ventilation) HCQ patie
10/12	LateAnnie et al., Phdeath, 14.3%, p=Hydroxychloroquine in hospitalized COVID-1Retrospective database analysis with PSM not including COVID-19 severity, finding mortality OR 0
10/11	LateSili et al., medRxiv, doi:10.1101/2020Factors associated with progression to criticAnalysis of hospitalized patients in Turkey showing HCQ was given to 99.2% of patients and the in
10/8	LateAparisi et al.,death, ↓63.0%, pLow-density lipoprotein cholesterol levels arRetrospective 654 hospitalized patients focused on low-density lipoprotein cholesterol levels, also
10/8	LateSoto-Becerra edeath, ↓18.1%, p<
10/6	LateDISCOVERY Trialdeath, ↓31.1%, pDISCOVERY Trial Preliminary ResultsEarly terminated DISCOVERY trial shows improvements in mortality and day 29 7-point ordinal sca
10/5	LateMori et al., Journal of Microbiology, ImTriple therapy with hydroxychloroquine, azithSmall case study of 5 patients in Japan showing improvement with HCQ+AZ+ciclesonide.
10/5	Early,Prodromos etmeta-analysisHydroxychloroquine is effective, and consistMeta analysis of 43 studies: "HCQ was found consistently effective against COVID-19 when used
10/2	LateNachega et al.,death, ↓27.6%, pClinical Characteristics and Outcomes of PatRetrospective 766 hospitalized patients in DRC showing mortality reduced from 29% to 11%, and i
10/1	LateAlmazrou et alventilation, ↓65.0Comparing the impact of HydroxychloroquinRetrospective 161 hospitalized patients in Saudi Arabia showing lower ventilation and ICU admissi
10/1	PrEP, Garcia-Albeniz cases, J22.0%, p Brief communication: A meta-analysis of ran Combination of the four underpowered prophylaxis RCTs to date showing statistically significant r
9/30	PEP <i>Polat et al., Me</i> cases, ↓57.0%, p Hydroxychloroquine Use on Healthcare Work Small prophylaxis study of 208 healthcare workers in Turkey, 138 with high risk exposure received
9/30	LateAyerbe et al., Ideath, \downarrow 52.2%, p<
9/30	PrEP, Ladapo et al., cases/death/hos Randomized Controlled Trials of Early Ambul Meta analysis of prophylactic and early treatment RCTs, 24% reduction in cases, hospitalization or

9/30	PrEPAbella et al., Jcases, ↓5.0%, p=Efficacy and Safety of Hydroxychloroquine vVery small early-terminated underpowered PrEP RCT with 64/61 HCQ/control patients and only 8 i
9/29	Late Lammers et al death/ICU, ↓32.0 Observational study 1,064 hospitalized patients in the Netherlands, 53% reduced risk of transfer to
9/29	Late Dabbous et al., Research Square, doi:1 A Randomized Controlled Study Of Favipiravi Small RCT comparing HCQ and favipiravir, with 50 patients in each arm, finding that 55.1% of HCQ
9/28	PEPLuco, J., Reseameta-analysisHydroxychloroquine as Post-Exposure ProphReanalysis of Boulware et al. PEP trial data showing statistically significant improvements with HCQ.
9/24	Early, Gasperetti et a safety analysis Arrhythmic safety of hydroxychloroquine in Safety study of 649 patients finding that HCQ administration is safe for short-term treatment for p
9/24	Late Shoaibi et al., death, 15.4% , p< Comparative Effectiveness of Famotidine in Retrospective database analysis focused on Famotidine but also showing results for HCQ users,
9/23	Late Ulrich et al., Op death, ↑6.0%, p= Treating Covid-19 With Hydroxychloroquine (Small RCT on very late stage use of HCQ, with 48% on oxygen at baseline. 67 HCQ patients, 61 co
9/22	LateSerrano et al.,death, 143.0%, pCOVID-19 and lung cancer: What do we know?Small retrospective study of 22 lung cancer patients, 14 treated with HCQ+AZ, showing HCQ+AZ
9/21	PrEPGentry et al., Ldeath, 186.7%, pLong-term hydroxychloroquine use in patientRetrospective patients with rheumatologic conditions showing zero mortality with HCQ, odds ratio
9/21	PrEPRajasingham ecases, $\downarrow 27.0\%$, pHydroxychloroquine as pre-exposure prophylPrEP RCT showing HR 0.73, $p = 0.12$. Trial halted after 47% enrollment, $p < 0.05$ will be reached at
9/21	PrEP Grau-Pujol et a cases, ↓67.9%, p Pre-exposure prophylaxis with hydroxychloro Small PrEP RCT showing that PrEP with HCQ is safe at the dosage used. No deaths, hospitalizatio
9/21	EarlyLofgren et al.,safety analysisSafety of Hydroxychloroquine among OutpatAnalysis of 2,795 outpatients not showing significant safety concerns with HCQ. No deaths were r
9/18	LateAxfors et al., mmeta-analysisMortality outcomes with hydroxychloroquineMeta analysis assigning 87% weight to the RECOVERY trial, producing the same result. The RECO
9/16	N/A <i>Karatza et al.,</i> dosing study Optimization of hydroxychloroquine dosing s Analysis of HCQ dosing, suggesting that high initial doses followed by low and sparse doses may

9/15	Late Ashinyo et al., hosp. time, 133.0 Clinical characteristics, treatment regimen a Retrospective 307 hospital patients in Ghana showing 33% reduction in hospitalization time with
9/14	LateLauriola et al.,death, 173.5%, p<
9/13	Early Sulaiman et al death, \downarrow 63.7%, p The Effect of Early Hydroxychloroquine-base Observational prospective 5,541 patients, adjusted HCQ mortality odds ratio OR 0.36, p = 0.012. A
9/12	LateHeberto et al.,death, \downarrow 53.6%, pImplications of myocardial injury in MexicanObservational prospective 254 hospitalized patients, HCQ+AZ mortality odds ratio OR 0.36, $p = 0.0$
9/9	LateAlamdari et al.,death, \downarrow 55.0%, pMortality Risk Factors among Hospitalized CRetrospective 459 patients in Iran 93% using HCQ, showing HCQ mortality RR 0.45, $p = 0.028$. HC
9/9	Early, <i>Kirenga et al.,</i> recov. time, 125 Characteristics and outcomes of admitted p Prospective 56 patients in Uganda, 29 HCQ and 27 control, showing 25.6% faster recovery with HCQ, 6
9/9	PrEP <i>Rentsch et al.,</i> death, ↑3.0% , p= Effect of pre-exposure use of hydroxychloro Observational database study of RA/SLE patients in the UK, 194,637 RA/SLE patients with 30,569
9/9	PrEP Laplana et al., cases, ↑56.0%, p Lack of protective effect of chloroquine deriv Survey of 319 autoimmune disease patients taking CQ/HCQ with 5.3% COVID-19 incidence, comp
9/7	ReviIHU, Expert RereviewNatural history and therapeutic options for CReview of the current state of knowledge regarding the natural history of and therapeutic options f
9/5	LateSynolaki et al.,death, ↓23.6%, pThe Activin/Follistatin-axis is severely deregRetrospective 117 patients, 58 HCQ showing lower mortality for HCQ patients. Version 1 of this pa
9/4	LateFurtado et al., The Lancet, doi:10.1016Azithromycin in addition to standard of careSmall RCT comparing the addition of AZ for very late stage patients on ventilation or oxygen. No si
9/2	In Vit Wang et al., Ph in vitro Chloroquine and hydroxychloroquine as ACE In Vitro study providing novel insights into the molecular mechanism of CQ/HCQ treatment, showi
9/2	Early Heras et al., Eu death, 195.6%, p COVID-19 mortality risk factors in older peop Retrospective 100 elderly nursing home patients, HCQ+AZ mortality 11.4% vs. control 61.9%, RR 0
9/2	PrEP <i>de la Iglesia</i> et hosp., ↑50.0% , p= Hydroxicloroquine for pre-exposure prophyyl

	Analysis of autoimmune disease patients on HCQ, compared to a control group from the general p
9/1	ReviHecel et al., PhreviewZinc(II)—The Overlooked Éminence Grise ofReview of zinc as an inhibitor of SARS-CoV-2's RNA-dependent RNA polymerase, and zinc ionopho
9/1	Early <i>Elbazidi et al., New Microbes and New</i> Pandemic and social changes, political fate Analysis of US states and countries. Country analysis shows a significant correlation between the
8/29	LateCastillo et al., Journal of Steroid BiochEffect of calcifediol treatment and best availRCT on calcifediol (25-hydroxyvitamin D) treatment for hospitalized COVID-19 patients showing si
8/28	LateFried et al., Clideath, ↑27.0%, p<
8/27	PrEP <i>Ferri at al., Clin</i> cases, <i>163.0%</i> , p COVID-19 and rheumatic autoimmune syste Analysis of 1641 systemic autoimmune disease patients showing csDMARD (HCQ etc.) RR 0.37, p
8/26	LateFiolet et al., Climeta-analysisEffect of hydroxychloroquine with or withoutMeta analysis of late stage studies (and one early treatment study with only 2 deaths), showing HCQ F
8/25	Early <i>Ip et al., medR</i> hosp., ↓45.9% , p= Hydroxychloroquine in the treatment of outp Retrospective 1,274 outpatients, 47% reduction in hospitalization with HCQ with propensity matchi
8/25	Late <i>Di Castelnuov</i> death, ↓30.0%, p< Use of hydroxychloroquine in hospitalised C Retrospective 3,451 hospitalized patients, 30% reduction in mortality with HCQ after propensity ad
8/24	Late Catteau et al., I death, ↓32.0%, p< Low-dose Hydroxychloroquine Therapy and Retrospective 8,075 hospitalized patients, 4,542 low-dose HCQ, 3,533 control. 35% lower mortality
8/21	EarlyLy et al., Interndeath, \downarrow 55.6%, pPattern of SARS-CoV-2 infection among depRetrospective analysis of retirement homes, HCQ+AZ >= 3 days mortality OR 0.37, p =0.02. 1690 el
8/21	N/ALane et al., Thesafety analysisRisk of hydroxychloroquine alone and in coRetrospective study of RA patients using HCQ vs. sulfasalazine (another DMARD). HCQ treatment
8/21	LateGonzalez et aldeath, ↓26.6%, pThe Prognostic Value of Eosinophil RecoveryRetrospective study focused on eosinophil recovery with 9,644 hospitalized patients in Spain, sho
8/20	LateDubernet et al.,ICU, ↓87.6%, p=0A comprehensive strategy for the early treatRetrospective analysis of 36 hospitalized patients showing HCQ/AZ associated with lower ICU ad
8/20	Early Prodromos , C., safety analysis Hydroxychloroquine is protective to the hear

	Review concluding that HCQ/AZ does not cause Torsade de Pointes or related deaths, HCQ decre
8/18	LatePinato et al., Cdeath, \downarrow 59.0%, p<Clinical portrait of the SARS-CoV-2 epidemicRestrospective 890 cancer patients with COVID-19, adjusted mortality HR for HCQ/CQ 0.41, p<0.0
8/15	LatePeters et al., Cldeath, ↑9.0%, p=Outcomes of Persons With COVID-19 in HosRetrospective study of HCQ use in 9 hospitals in the Netherlands, showing no significant differenc
8/14	Late Abd-Elsalam e death, ↑20.0%, p Hydroxychloroquine in the Treatment of COV Small RCT in Egypt with 97/97 HCQ/control patients, showing 58% more recovery @28days for HCQ (
8/13	LateRecord et al., Jdeath, ↑37.7%, pEfficacy of hydroxychloroquine and tocilizumRetrospective 176 hospitalized patients (144 HCQ, 32 control) showing no significant differences
8/11	EarlyBakhshaliyev esafety analysisThe effect of 5-day course of hydroxychloroSafety study of 109 patients showing 5 days of HCQ+AZ did not lead to clinically significant QT pr
8/11	Late Saleemi et al., viral- time, †21.0 Time to negative PCR from symptom onset i Retrospective 65 HCQ+AZ, 20 control patients, showing median time to negative PCR of 23 days f
8/8	LateLopez et al., Int. J. Antimicrob. Agents,Effects of Hydroxychloroquine on Covid-19 iSmall retrospective study of 29 ICU patients comparing those with HCQ plasma concentration wit
8/6	ReviMcCullough etreviewPathophysiological Basis and Rationale for EReview of pathophysiological principles related to early outpatient treatment and therapeutic appr
8/6	PEP, Watanabe et al meta-analysis Concerns regarding the misinterpretation of Open letter signed by 38 professors and doctors regarding misinterpretation of statistics in HCQ R
8/5	PrEP Singer et al., A cases, ↑9.0%, p= Hydroxychloroquine ineffective for COVID-19 Comparison of the percentage of SLE/RA patients on immunosuppressants that were taking HCQ,
8/5	LateKalligeros et aldeath, ↑67.0%, pHydroxychloroquine use in hospitalised patieSmall retrospective database analysis of 36 patients receiving HCQ not showing significant differe
8/4	Late <i>Kamran et al.,</i> progression, 15.0 Clearing the fog: Is HCQ effective in reducing Study of 349 low-risk hospitalized patients with 151 non-consenting or ineligible patients used as
8/3	LateBerenguer et adeath, ↓61.9%, p<Characteristics and predictors of death amoRetrospective 4035 hospitalized patients in Spain showing reduced mortality with HCQ (data is in
8/3	

	LateYu et al., Science China Life Sciences,Beneficial effects exerted by hydroxychloroqRetrospective 2,882 patients in China, median age 62, 278 receiving HCQ, median 10 days post ho
8/2	LateDavido et al., Iint./hosp., \$5.0Impact of medical care including anti-infectiRetrospective of 132 hospitalized patients. HCQ+AZ(52)/AZ(28) significantly reduced death/ICU,
8/2	In Vit Sheaff, R., bio in vitro A New Model of SARS-CoV-2 Infection Base In vitro study presenting a new theory on SARS-CoV-2 infection and why HCQ/CQ provides benefit
7/31	Mazzitelli et al., Travel Medicine and I Apparent inefficacy of hydroxychloroquine c Report on HCQ+AZ use in 41 elderly high-risk patients. 29 of 30 patients with treatment >= 5 days
7/29	LateD'Arminio Mondeath, \downarrow 34.0%, pEffectiveness of Hydroxychloroquine in COVIHCQ+AZ adjusted death HR 0.44, p=0.009. Propensity scores include baseline COVID-19 disease s
7/28	Late BaŞaran et al., Turk. J. Med. Sci., doi:1 Outcome of Non-Critical COVID-19 Patients Observational study of 174 hospitalized patients in Turkey, median age 45.4, 23 treated with HCQ,
7/26	PEP <i>Mitjà et al., NE</i> death, J32.0%, p A Cluster-Randomized Trial of Hydroxychlor Death rate reduced from 0.6% to 0.4%, RR 0.68, not statistically significant due to low incidence (8
7/24	PrEP <i>Khurana et al.,</i> cases, 151.0% , p Prevalence and clinical correlates of COVID Study of hospital health care workers showing HCQ prophylaxis reduces COVID-19 significantly, O
7/23	LateCavalcanti et adeath, ↓16.0%, pHydroxychloroquine with or without AzithroLate stage RCT of 667 hospitalized patients with up to 14 days of symptoms at enrollment and re
7/22	In Vit <i>Hoffmann et al in vitro</i> Chloroquine does not inhibit infection of hu The title of this paper does not appear to match the results. Fig. 1b @100uM shows CQ results in
7/22	LateRivera et al., Cdeath, ↑2.4%, p=Utilization of COVID-19 Treatments and CliniRetrospective cancer patients, showing adjusted OR 1.03 [0.62-1.73] for HCQ. The study reports th
7/22	LateKelly et al., Britideath, ↑143.0%,Clinical outcomes and adverse events in patiRetrospective 82 hospitalized patients HCQ/AZ, 52 SOC, not finding statistically significant differe
7/21	LateBernaola et al.,death, ↓17.0%, p<
7/20	PrEP <i>Desbois et al., Research Square, doi:1</i> Prevalence and clinical features of COVID-19 Retrospective 199 sarcoidosis patients showing RR 0.83, <i>p</i> =1.0.

7/20	EarlyRisch, H., Amemeta-analysisResponse to: "Early Outpatient Treatment ofUpdated meta analysis including 7 new studies of high-risk outpatients, for a total of 12 studies, al
7/18	PEPWatanabe, M.,meta-analysisEfficacy of Hydroxychloroquine as ProphylaxSecondary analysis of Boulware et al.'s PEP trial and treatment delay-response data, confirming th
7/19	Late McGrail et al., death, ↑70.0%, p COVID-19 Case Series at UnityPoint Health S HCQ+AZ early in the epidemic had a fairly good success rate with few complications, 86% of HCQ
7/17	Late Lyngbakken et death, 13.7%, p= A pragmatic randomized controlled trial repo Small RCT of nasopharyngeal viral load not showing significant differences. The rate of reduction
7/16	Early Hong et al., Inf viral+, 164.9%, p= Early Hydroxychloroquine Administration for HCQ 1-4 days from diagnosis was the only protective factor against prolonged viral shedding foun
7/16	Early <i>Skipper et al.,</i> no recov., ↓20.0% Hydroxychloroquine in Nonhospitalized Adul ~70 to 140 hour (inc. shipping) delayed outpatient treatment with HCQ reduced combined hospita
7/16	Early <i>Mitjà</i> et al., Cli hosp., ↓25.0%, p= Hydroxychloroquine for Early Treatment of A This paper has inconsistent data - some of the values reported in Table 2 and the abstract corresp
7/15	LateGupta et al., JAdeath, ↑6.0%, p=Factors Associated With Death in Critically IIIAnalysis of 2215 intensive care unit patients showing no significant differences with this very late
7/14	Late <i>Trullàs et al., R</i> death, J35.6% , p High in-hospital mortality due to COVID-19 in Retrospective 100 hospitalized patients in Spain showing lower mortality with HCQ+AZ.
7/14	Early Chowdhury et al., Research Square, do A Randomized Trial of Ivermectin-Doxycyclin Small 116 patient RCT comparing Ivermectin-Doxycycline and HCQ+AZ, not showing a significant
7/11	Late Lecronier et al death, 142.0%, p Comparison of hydroxychloroquine, lopinavir Retrospective 80 ICU patients, 22 SOC, 20 lopinavir/ritonavir, 38 HCQ. 28 day mortality 24% (HCQ)
7/10	Late Cravedi et al., death, \uparrow 53.0%, p COVID-19 and kidney transplantation: Result Analysis of 144 hospitalized kidney transplant patients showing HCQ mortality HR 1.53, $p = 0.17$
7/10	LateChen et al., meviral+, ↓24.0%, p=A Multicenter, randomized, open-label, contr2 very small studies with hospitalized patients in Taiwan. RCT with 21 treatment and 12 SOC patie
7/9	LateRivera-Izquierddeath, ↓19.0%, pAgentes terapéuticos utilizados en 238 paciRetrospective 238 hospitalized patients in Spain showing lower mortality with HCQ, adjusted haza

7/9	Early, Raoult et al., Pr meta-analysis Hydroxychloroquine and Azithromycin as a T Updated meta analysis showing significant reductions in mortality and viral shedding. Mortality O
7/8	N/AMarzolini et aldosing studyEffect of Systemic Inflammatory Response tStudy of Lopinivar and HCQ plasma concentrations and CRP levels in late stage (treatment initiati
7/8	N/ALi et al., Cell DereviewIs hydroxychloroquine beneficial for COVID-1Review of the anti-inflammatory, antiviral, and protective vascular effects of CQ and HCQ, noting th
7/7	ReviGoldstein, L., PreviewHydroxychloroquine-based COVID-19 Treat85% of globally surveyed physicians recognized HCQ as at least partially effective in treating COVI
7/7	LateAn et al., medRviral+, \downarrow 3.0%, p=0Treatment Response to HydroxychloroquineRetrospective of hospitalized patients with 31 HCQ patients and 195 standard treatment patients,
7/3	PrEPZhong et al., Lcases, ↓91.0%, pCOVID-19 in patients with rheumatic diseaseRheumatic disease patients on HCQ had a lower risk of COVID-19 than those on other disease-mo
7/1	LateArshad et al., Ideath, ↓51.3%, pTreatment with Hydroxychloroquine, AzithroHCQ decreases mortality from 26.4% to 13.5% (HCQ) or 20.1% (HCQ+AZ). Propensity matched HC
7/1	N/ASamuel et al.,safety analysisIncidence of arrhythmias and electrocardiogIn pediatric patients with PCR positive active COVID-19 infection, significant arrhythmias are infreq
6/30	Late Martinez-Lope death, ↓33.0%, p Multiple Myeloma and SARS-CoV-2 Infection Retrospective 167 multiple myeloma patients in Spain
6/30	Late <i>Mikami et al., J</i> death, ↓47.0%, p< Risk Factors for Mortality in Patients with C HCQ decreases mortality, HR 0.53 (CI 0.41–0.67). IPTW adjustment does not significantly change
6/30	Late <i>Komissarov et</i> viral load, †25.0% Hydroxychloroquine has no effect on SARS Small late stage (7-10 days post symptoms) study of nasal swab RNA with 12 control and 33 pati
6/29	Late Sosa-García et death, $\uparrow 10.5\%$, p Experience in the management of severe CO Small retrospective study of 56 ICU patients in Mexico showing HCQ RR 1.1, $p = 1.0$.
6/29	PrEPFerreira et al.,cases, \$47.1%, pChronic treatment with hydroxychloroquineChronic treatment with HCQ provides protection against COVID, odds ratio 0.51 (0.37-0.70). The a
6/29	N/A <i>Mfeukeu-Kuat</i> safety analysis Electrocardiographic safety of daily Hydroxy No life-threatening modifications of the QT interval was observed in non-severe COVID-19 patients

6/25	PrEP Gendebien et a cases, 13.9%, p= Systematic analysis of COVID-19 infection a Small study of 152 SLE patients taking HCQ with a phone survey for COVID-19 suggestive sympto
6/25	EarlyLagier et al., Trdeath, 159.0%, pOutcomes of 3,737 COVID-19 patients treateEarly treatment leads to significantly better clinical outcome and faster viral load reduction. Match
6/23	LateBousquet et aldeath, ↓42.8%, pADL-dependency, D-Dimers, LDH and absencObservational prospective 108 hospitalized patients 65 and older, showing HCQ mortality OR 0.49,
6/22	Late Fontana et al., death, \downarrow 50.0%, p SARS-CoV-2 infection in dialysis patients in n Very small observational study of 15 dialysis patients showing HCQ mortality RR 0.50, $p = 0.53$.
6/22	Early Chen et al., me viral- time, \72.0 Efficacy and safety of chloroquine or hydrox Significantly faster clinical recovery and shorter time to RNA negative (from 7.0 days to 2.0 days (
6/21	Late <i>Faíco-Filho et</i> viral rate, ↓80.8%, No benefit of hydroxychloroquine on SARS-C Viral load comparison for 34 HCQ and 32 control patients hospitalized with moderate COVID-19. A
6/19	PrEPSMSH SawainewsHCQ beneficial as preventive drug: SMS doctPrEP with 4,300 very high risk healthcare workers in a hospital with up to 500+ COVID patients at a
6/19	LateNIH, study notnewsNIH halts clinical trial of hydroxychloroquineNIH halts late stage trial reporting no harm and no benefit. 470 patients.
6/19	LateSbidian et al.,death, ↑5.0%, p=Hydroxychloroquine with or without azithroRetrospective of 4,642 hospitalized patients in France showing significantly faster discharge with
6/19	N/AKaptein et al.,animal studyFavipiravir at high doses has potent antiviralAnimal study with Syrian hamsters, showing treatment of SARS-CoV-2-infected hamsters with favi
6/18	LatePaccoud et al.,death, ↓11.0%, pCompassionate use of hydroxychloroquine iRetrospective of 89 hospitalized patients, survival HR 0.89 [0.23-3.47], not statistically significant
6/17	Early <i>Capucci et al., J. Cardiovasc. Med. 21,</i> Low hospitalization rate without severe arrhy Prospective analysis of early treatment of 350 patients in Italy (without waiting for PCR results), sh
6/17	LateXue et al., J. Med. Virology, June 17, 2Hydroxychloroquine treatment in COVID-19:30 hospitalized patients. Early use of HCQ is more effective, 43% reduction in progression from m
6/17	Late <i>Luo</i> et al., Ann death, \uparrow 2.2%, p= COVID-19 in patients with lung cancer Analysis of hospitalized lung cancer patients with 35 of 48 taking HCQ, mortality OR 1.03, $p = 0.99$.

6/16	Late <i>Kim et al., Korean J Intern Med, doi:10</i> Lopinavir-ritonavir versus hydroxychloroquin Small retrospective study of hospitalized patients with 31 lopinavir-ritonavir and 34 HCQ patients,
6/16	PrEPWHIP COVID-1newsHenry Ford Health System still moving forwaOngoing WHIP COVID-19 HCQ PrEP study reports analyzing their data and seeing a significantly i
6/16	PrEPHuang et al., Ahosp., ↓80.0%, p<
6/12	TheoScherrmann, AtheoryIntracellular ABCB1 as a Possible MechanisTheory paper, not included in the study count or percentages. Proposes a new mechanism suppor
6/12	LateGiacomelli et al., Journal of Medical ViEarly administration of lopinavir/ritonavir pluLate stage study of hospitalized patients comparing treatment starting within 5 days versus later
6/10	LateWang et al., mdeath, \downarrow 5.8%, p=Comorbidity and Sociodemographic determiDatabase analysis of 7,592 patients in NYC, showing adjusted HCQ mortality odds ratio OR 0.96, p
6/10	Early Otea et al., medRxiv, doi:10.1101/2020 A short therapeutic regimen based on hydro 80 moderate cases, HCQ+AZ appears to reduce serious complications and death. Moderate treate
6/9	 Early <i>Pirnay et al., Hosp. Pharm. and Clinici</i> Beneficial effect of Hydroxychloroquine-Azit 68 very high risk nursing home residents, median age 86, HCQ+AZ early treatment within 2.5 days
6/9	PrEPBhattacharyacases, ↓80.7%, pPre exposure Hydroxychloroquine use is assHCQ reduced cases from 38% to 7%. 106 people. No serious adverse effects.
6/6	ReviRoussel et al.,reviewInfluence of conflicts of interest on public poShows a correlation (Spearman test, $p = 0.017$) between the amount received from Gilead Science
6/6	Early,Million et al., Nmeta-analysisClinical Efficacy of Chloroquine derivatives in[H]CQ effective and reduces mortality by a factor 3. Meta analysis of 20 studies.
6/5	Late RECOVERY Col death , ↑9.0% , p= Effect of Hydroxychloroquine in Hospitalized RECOVERY trial finds no significant benefit for very late stage very sick patients. Results may be d
6/3	PEPBoulware et alcases, \$17.0%, pA Randomized Trial of Hydroxychloroquine aCOVID-19 cases are reduced by [49%, 29%, 16%] respectively when taken within ~[70, 94, 118] hou
6/1	N/A <i>Al-Kofahi</i> et al., dosing study Finding the Dose for Hydroxychloroquine Pro

	Analysis of HCQ dosing regimens, recommending: PrEP: 800mg loading dose followed by 400mg
5/31	Early <i>Guérin et al., A</i> death, ↓61.4%, p Azithromycin and Hydroxychloroquine Accel Mean clinical recovery time reduced from 26 days (SOC) to 9 days, <i>p</i> <0.0001 (HCQ+AZ) or 13 days
5/28	LateChamieh et al., medRxiv 2020.05.28.2Viral Dynamics Matter in COVID-19 PneumoHCQ+AZ potentially explains 94.7% success in treating a fairly complex cohort.
5/28	PrEPChatterjee et acases, 166.8%, pHealthcare workers & SARS-CoV-2 infection i4+ doses of HCQ associated with a significant decline in the odds of getting infected, dose-respon
5/28	LateHuang et al., Nviral- time, ↓67.0Preliminary evidence from a multicenter pro197 CQ patients, 176 control. Mean time to undetectable viral RNA and duration of fever significan
5/27	Late Goldman et al., death, ↓22.3%, p Remdesivir for 5 or 10 Days in Patients with Study focused on remdesivir but with results for HCQ in the supplementary appendix, showing 9%
5/28	Late Kuderer et al., death, ↑134.2%, Clinical impact of COVID-19 on patients with Retrospective 928 cancer patients, showing HCQ OR 1.06 [0.51-2.20]. HCQ+AZ OR 2.93 [1.79-4.79]
5/28	PrEP <i>Gianfrancesco</i> hosp., J3.3% , p=0 Characteristics associated with hospitalisati Analysis of rheumatic disease patients showing no significant association between antimalarial th
5/27	EarlyRisch, Americameta-analysisEarly Outpatient Treatment of Symptomatic,Five studies, including two controlled clinical trials, have demonstrated significant outpatient treat
5/25	LateIp et al., medRdeath, ↓1.0%, p=Hydroxychloroquine and Tocilizumab TherapRetrospective study of late stage use on 2,512 hospitalized patients showing no significant differe
5/22	PEP,ICMR, Indian CadvisoryRevised advisory on the use of HydroxychlorHealthcare workers on HCQ prophylaxis less likely to get COVID. Significant dose-response relatio
5/22	LateMehra et al., TretractedHydroxychloroquine or chloroquine with or wIncorrect at first read (implausible death, ventilation, and population numbers). This paper was retr
5/19	LateSingh et al., mdeath, ↓5.0%, p=Outcomes of Hydroxychloroquine TreatmentEHR analysis of 3,372 hospitalized COVID-19 patients not showing a significant difference for mor
5/18	LateKim et al., medhosp. time, ↓51.0Treatment Response to Hydroxychloroquine,Retrospective of 97 moderate cases. Time to viral clearance significantly shorter for HCQ+antibiot
5/18	Early Ahmad et al., doi:10.1101/2020.05.18 Doxycycline and Hydroxychloroquine as Trea

	54 patients in long term care facilities. 6% death with HCQ+AZ compared to 22% using a naive indi
5/16	PrEPMacias et al.,hosp., 125.5%, p=Similar incidence of Coronavirus Disease 20Very small retrospective study of rheumatic disease patients, sample size is too small for statistic
5/15	LateYu et al., Sciendeath, $\downarrow 60.5\%$, pLow Dose of Hydroxychloroquine Reduces FRetrospective, 550 critically ill patients. 19% fatality for HCQ versus 47% for non-HCQ, RR 0.395, p
5/14	Late <i>Mahévas et al.,</i> death, ↑20.0% , p Clinical efficacy of hydroxychloroquine in pat Observational study of 181 patients with advanced disease requiring oxygen showing no benefit f
5/13	LateOkour et al., Journal of PharmacokinetHydroxychloroquine and azithromycin as potOdds of PCR-positive decrease by 53% for each unit increase in HCQ log-concentration. Similarly, t
5/12	PrEP Cassione et al cases, ↑49.6%, p COVID-19 infection in a northern-Italian coho Survey of 165 SLE patients, 127 on HCQ. 8 patients with suspected COVID-19 and 4 confirmed ca
5/11	Late Shabrawishi et viral+, ↓14.7%, p= Negative nasopharyngeal SARS-CoV-2 PCR Retrospective 93 hospitalized patients in Saudi Arabia showing a non-statistically significant 15% r
5/11	LateResenberg etdeath, ↑35.0%, pAssociation of Treatment With HydroxychlorRestrospective observational late stage study showing no significant differences but calling for cli
5/10	Late Alberici et al., death, \downarrow 42.9%, p A report from the Brescia Renal COVID Task Analysis of 94 hemodialysis COVID-19 positive patients. Reduction in death seen with HCQ but p =
5/8	Ex ViGrassin-Delyleex vivoChloroquine Inhibits the Release of InflammOn human lung parenchymal explants, CQ concentration clinically achievable in the lung (100 μ M)
5/8	LateCarlucci et al., J. Med. Microbiol., SepZinc sulfate in combination with a zinc ionopRetrospective 932 patients. Addition of Zinc to HCQ+AZ reduces mortality / transfer to hospice, IC
5/7	PrEPKonig et al., Anhosp., ↓3.0%, p=0Baseline use of hydroxychloroquine in systeAnalysis of 80 SLE patients diagnosed with COVID-19, showing the frequency of hospitalisation di
5/7	TheoDerendorf, H., ItheoryExcessive lysosomal ion-trapping of hydroxyDiscusses pharmacokinetic properties of HCQ+AZ as a potential underlying mechanism of the ob
5/7	Late Geleris et al., N int./death, ↑4.0%, Observational Study of Hydroxychloroquine i There appears to be a major error in this paper. Before propensity matching, 38 control patients ha
5/7	

	N/A HCQ use	Sermo (News) d by 55% of physicia	news Ins worldwide for COVI	Sermo reports: COVID-19 treatment trends o D. Survey of 6,150 physicians.
5/6	N/A Monkey s	Maisonnasse study which reports	animal study no effect of HCQ or HC	Hydroxychloroquine use against SARS-CoV Q+AZ. However, there are several signs of effe
5/5	Late 166 patie	<i>Membrillo de</i> ents hospitalised wit	death, ↓ 55.1% , p h COVID-19, HCQ increa	Early Hydroxychloroquine Is Associated with ased survival 1.4 - 1.8 times when patients ad
5/5	Early, Retrospe		l Med Infect Dis., 20 HCQ+AZ safe and resu	Early Treatment of COVID-19 Patients With Ilts in a low fatality rate.
5/5	PrEP Very sma		cases, ↓ 8.1%, p= c disease/autoimmune	Continuous Hydroxychloroquine or Colchicin disorder patients showing no significant diffe
5/5	PrEP Analysis	<i>Mitchell et al.,</i> of COVID-19 among		Markedly Lower Rates of Coronavirus Infecti wide counterintuitive disparity between well
5/4	PrEP Database		cases, ↑ 47.7% , p rugs and COVID-19 cas	Association of previous medications with th ses, with 23 cases taking HCQ, and 251 control
5/1	N/A Study of	<i>Mercuro</i> et al., 90 hospitalized patie		Risk of QT Interval Prolongation Associated receiving AZ, 53% hypertension, 29% diabete
5/1	N/A Study of	<i>Bessière</i> et al., 40 very serious cono		Assessment of QT Intervals in a Case Series required invasive mechanical ventilation, 63%
5/2	Late Prelimina	Seydi (News) (ary results of Senega	news Il trial with 181 patients	Coronavirus: a study in Senegal confirms the showing faster recovery with HCQ, and even f
4/30	Early Analysis		. Med. Pharmacol alaria, finding that COVI	Efficacy of chloroquine and hydroxychloroqu D-19 is highly pandemic in countries where m
4/27	Late Analysis		death, ↓ 45.9% , p enal replacement thera	Status of SARS-CoV-2 infection in patients o by. Statistically significant reduction in mortalit
4/29	N/A 201 hosp	Saleh et al., Cir italized patients. No	safety analysis serious side effects of	The Effect of Chloroquine, Hydroxychloroqui HCQ. No instances of Torsade de pointes, or
4/25	In Vit HCQ and	Andreani et al., AZ has a synergistic	<i>in vitro</i> c effect <i>in vitro</i> on SARS	In vitro testing of combined hydroxychloroqu S-CoV-2 at concentrations compatible with tha

4/24	Early Ashraf et al., m death, ↓67.5%, p COVID-19 in Iran, a comprehensive investiga Small limited trial with 100 patients concluding that HCQ improved clinical outcome, OR 0.016 [0.0
4/21	Early <i>Izoulet M., SSR</i> death, ↓85.0%, p< Countries which Primarily Use Antimalarial D Compares the dynamics of daily deaths in the 10 days following the 3rd death in countries using a
4/21	LateMagagnoli et adeath, ↓11.0%, pOutcomes of hydroxychloroquine usage in URetrospective 807 hospitalized patients, no statistically significant reduction in mortality or the ne
4/17	PEPLee at al., Int. J. Antimicrob. Agents, 2Can Post-Exposure Prophylaxis for COVID-1Post exposure prophylaxis of 211 high-risk people after major exposure event in a long term care
4/16	LateBorba et al., JAMA Network Open, doi:Chloroquine diphosphate in two different doComparison of typical CQ dosage with high dosage CQ (600mg CQ twice daily for 10 days), showi
4/15	Early, <i>Esper et al., Pr</i> hosp., \64.0% , p= Empirical treatment with hydroxychloroquine 636 patients. HCQ+AZ reduced hospitalization 79% when used within 7 days (65% overall). Non-ra
4/15	TheoBrufsky, A., JtheoryHyperglycemia, hydroxychloroquine, and theTheory on the effectiveness of HCQ. HCQ has been shown to block the polarization of macrophag
4/14	LateTang et al., BMviral+, 121.4%, p=Hydroxychloroquine in patients with COVID150 patients very late stage RCT showing no significant difference. Treatment very late, average 1
4/13	LateGao et al., BiosreviewUpdate on Use of Chloroquine/HydroxychlorIncreasing evidence from completed clinical studies shows CQ and HCQ effective (HCQ more effe
4/12	LateBarbosa et al.,death, ↑147.0%,Clinical outcomes of hydroxychloroquine inSmall retrospective study with 63 patients (32 treated with HCQ), showing no effectiveness, howe
4/11	Early Gautret et al., Travel Medicine and Infe Clinical and microbiological effect of a comb Pilot study suggesting improvement with HCQ+AZ and recommending further study. 80 patients
4/10	LateLover, medRxivmeta-analysisQuantifying treatment effects of hydroxychloSecondary analysis of Gautret et al. showing "modest to no impact of HCQ treatment, with more si
4/3	TheoFantini et al., IntheoryStructural and molecular modelling studies rIn-silico analysis confirming the antiviral properties of CQ, showing a new mechanism of action of CQ,
4/1	Early Huang et al., J no recov., 191.7% Treating COVID-19 with Chloroquine 22 patients. All CQ patients discharged by day 14 versus 50% of Lopinavir/Rotinavir patients. Sym

3/31	Late Chen et al., me pneumonia, ↓57 Efficacy of hydroxychloroquine in patients wi 62 patients. RCT showing significantly faster recovery with HCQ. 13% progressed to severe cases
3/31	In Vit <i>Clementi et al., in vitro</i> Combined Prophylactic and Therapeutic Use <i>In vitro</i> study, not included in the study count or percentages, showing greater inhibition for combi
3/28	LateMolina et al., Médecine et Maladies InfNo evidence of rapid antiviral clearance or cliReport on 11 patients treated with HCQ with no control group. Authors suggest there is no eviden
3/26	LateZhong Nanshaviral+, ↓80.0%, p<
3/24	TheoPagliano et al.,theoryIs Hydroxychloroquine a Possible Post-ExpoCQ and HCQ inhibit replication at early stages of infection, no similar effect reported for other drug
3/23	TheoHu et al., NaturtheoryInsights from nanomedicine into chloroquinCQ is known in nanomedicine research for the investigation of nanoparticle uptake in cells, and m
3/21	PrEPICMR, Indian CadvisoryAdvisory on the use of hydroxy-chloroquineRecommends HCQ for prophylaxis in asymptomatic healthcare workers as found effective in-vitro
3/20	LateHu et al., ShannewsShanghai Experience of COVID-19 ManagemClinical studies of HCQ with 184 cases and 21 hospitals show HCQ is effective.
3/18	In VitLiu et al., Cellin vitroHydroxychloroquine, a less toxic derivative oHCQ effective in vitro and less toxic than CQ. In addition to direct antiviral activity, HCQ is a safe an
3/17	Early Gautret et al., I viral+, $\downarrow 66.0\%$, p= Hydroxychloroquine and azithromycin as a tr HCQ was significantly associated with reduction / elimination of viral load, which was enhanced w
3/17	N/ASahraei et al., IreviewAminoquinolines against coronavirus diseasDiscussion of mechanisms of action, CQ vs. HCQ, early studies, safety.
3/13	N/ATodaro and RireviewAn Effective Treatment for Coronavirus (COVDiscussion of existing research, treatment guidelines, and mechanisms of action for CQ and HCQ,
3/12	TheoDevaux et al., ItheoryNew insights on the antiviral effects of chlorDiscusses mechanisms of CQ interference with the SARS-CoV-2 replication cycle.
3/10	N/A <i>Cortegiani et a</i> meta-analysis A Systematic Review on the Efficacy and Saf Review of six articles and 23 ongoing clinical trials in China recommending research and clinical u

3/9	N/A HCQ is me	Yao et al., Clin ore potent than CQ		In Vitro Antiviral Activity and Projection of Op RS-CoV-2. Simulates HCQ concentration in lu
3/6	Late	<i>Chen et al., J</i>	progression, ↓ 29.	A pilot study of hydroxychloroquine in treatm
	30 moder	ate hospitalized cas	ses, all recovered. Time	to RNA negative comparable. Less frequent r
3/4	Late	Colson et al., I	review	Chloroquine and Hydroxychloroquine as Avai
	Recomme	ending CQ and HCQ	for COVID-19 based or	20 clinical studies in China and a strong ratio
2/20	Late Early trials	-	. Tuberc. Respir. Di results in shorter hospi	Expert Consensus on Chloroquine Phosphat tal stays and improved patient outcomes.
2/19	Late Results fr		nce Trends, 2020, d in China showing CQ is	Breakthrough: Chloroquine phosphate has s effective.
2/17	Late	Sun, Y., deputy	news	Antimalarial drug confirmed effective on CO
	HCQ unde	er clinical trials in >1	0 hospitals in China an	d has shown fairly good efficacy.
2/11	Late Early resu	Xia et al., ChiC Its from a very sma		Efficacy of Chloroquine and Lopinavir/ Riton ne application for a later trial. Very minimal de
2/4	In Vit	Wang et al., Ce	<i>in vitro</i>	Remdesivir and chloroquine effectively inhibi
	In vitro stu	udy, not included in t	the study count or perc	entages. Remdesivir and CQ potently blocked
2017	N/A	<i>Chhonker</i> et al	dosing study	Simultaneous quantitation of hydroxychloro
	Presents a	a method for quanti	ification of HCQ in mou	se blood and tissues. They show a lung conce
2014	Anim	Browning, D., P	animal study	Pharmacology of Chloroquine and Hydroxychlor
	Review of	the pharmacology	of CQ and HCQ. Some I	notable points: - HCQ and CQ are equipotent b
2014	In Vit CQ inhibit	de Wilde et al., s SARS-CoV, MERS-		Screening of an FDA-Approved Compound Li FP replication in the low-micromolar range.
2012	Anim CQ, a kno	Yan et al., Cell wn autophagy inhib	-	Anti-malaria drug chloroquine is highly effect e, can efficiently ameliorate acute lung injury a
2009	Anim CQ inhibit	<i>Keyaerts</i> et al., s HCoV-OC43 replic	-	Antiviral Activity of Chloroquine against Hum lethal HCoV-OC43 infection in newborn C57B
2008	In Vit	Kono et al., Ant	in vitro	Inhibition of human coronavirus 229E infecti
	CQ signifi	cantly decreased vii	ral replication of HCoV-2	229E at concentrations lower than in clinical u

2006	In Vit Update to		in vitro cluded in the study cour	New insights into the antiviral effects of chlo nt or percentages. Hypothesis of CQ inhibiting
2005			in vitro ot included in the study	Chloroquine is a potent inhibitor of SARS cor count or percentages. CQ has strong antiviral
2004		-		In vitro inhibition of severe acute respiratory count or percentages. IC50 of CQ for antiviral
2003			theory Int or percentages. Disc	Effects of chloroquine on viral infections: an sussion/review noting that CQ exerts antiviral
1918	N/A Quinine v		al Record, 97:6, 235, ctive for the Spanish Flu	A confirmatory report upon the abortive acti u in 1918.
1890	N/A Quinine a	(-	news erapy for defying death	Quinine use for the Russian influenze pande during the Russian influenza pandemic of 18
1889	N/A Quinine h	-		Laxative Bromo Quinine the 1889. Not included in the study count or per